Rotkreuzklinikum München

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer (2026) Van Mackelenbergh MT, Pfarr N, Weber K, Untch M, Solbach C, Schneeweiss A, Jank P, et al. Journal article Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Clinical significance of micrometastases: Data from five neoadjuvant studies (2026) Warnecke FJ, Holtschmidt J, Schneeweiss A, Fasching P, Untch M, Link T, Schmatloch S, et al. Journal article Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials (2025) Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C, Untch M, et al. Journal article Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX) (2025) Link T, Reinisch M, Just M, Untch M, Filmann N, Stötzer O, Denkert C, et al. Journal article Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial (2025) Kolberg HC, Schumacher J, Erber R, Braun M, Fasching P, Grischke EM, Schem C, et al. Journal article Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer (2025) Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, Denkert C, et al. Journal article Surface-based deep inspiration breath-hold radiotherapy in left-sided breast cancer: final results from the SAVE-HEART study (2024) Schönecker S, Angelini L, Gaasch A, Zinn A, Konnerth D, Heinz C, Xiong Y, et al. Journal article Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial (2024) Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, et al. Journal article Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial(Nature Medicine, 10.1038/s41591-024-03261-7) (2024) Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, et al. Journal article, Erratum Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (2024) Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, et al. Journal article